Cipemastat
| Cipemastat | |
|---|---|
|
(2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-(piperidin-1-yl)-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide |
|
| Identifiers | |
| CAS number | 190648-49-8 |
| PubChem | 9824350 |
| ChemSpider | 8000097 |
| ChEMBL | CHEMBL467686 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C22H36N4O5 |
| Molar mass | 436.55 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Cipemastat (rINN, also known as Ro 32-3555 and by the tentative trade name Trocade) is a selective inhibitor of matrix metalloproteinase-1 that has been investigated as an anti-arthritis agent.[1] It is being developed by Roche.
[edit] References
- ^ Hemmings F, Farhan M, Rowland J, Banken L, Jain R (2001). "Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis". Rheumatology (Oxford) 40 (5): 537–43. doi:10.1093/rheumatology/40.5.537. PMID 11371662.
| This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |